iShares Core S&P Small-Cap
Is Tesla Bear Jim Chanos Buying Something New?
Jim Chanos, the founder and president of Kynikos Associates, is a long-time short-seller of Tesla stock. Tesla stock has fallen 17.5% in the last year.
Aveo Pharmaceuticals Stock Fell More than 60% on January 31
On January 31, Aveo Pharmaceuticals (AVEO) issued a press release announcing its decision not to file an NDA for Fotivda (tivozanib).
Why iRobot Stock Has Surged ~5% Today
Today, iRobot (IRBT) stock surged 5.3% before the market opened.
A Financial Overview of Supernus Pharmaceuticals in September
In Q2 2018, Supernus Pharmaceuticals (SUPN) reported net revenues of $99.5 million compared to $75.8 million in Q2 2017.
Analyzing Flotek Industries’ 4Q17 Performance by Segment
Flotek Industries (FTK) is 0.04% of the iShares Core S&P Small-Cap ETF (IJR). IJR increased 8% in the past year, versus a 56% decrease in FTK’s stock price during the period.
Behind MiMedx Group’s Recent Financial Performance
In 3Q17, MiMedx Group’s (MDXG) net sales rose to $84.6 million, compared with $64.4 million in 3Q16—a 31% YoY (year-over-year) rise.
Analysts’ Ratings for Nektar Therapeutics in January 2018
San Francisco–based biopharmaceutical company Nektar Therapeutics (NKTR) develops drug candidates that make use of its advanced polymer conjugate technology platforms.
Analysts’ Recommendations for Spectrum Pharmaceuticals
Biotech firm Spectrum Pharmaceuticals (SPPI) develops oncology and hematology drug products. SPPI generates ~90% of its revenues from the US market, and ~10% of its revenues come from Europe.
Analyst Recommendations for Nektar Therapeutics in November 2017
In 3Q17, Nektar Therapeutics (NKTR) reported revenues of $152.9 million, a YoY rise of 320.7%. The sudden spurt is mainly due to the upfront payment of $150 million from Eli Lilly.
Analysts’ Recommendations for PetMed Express and Peers in 2017
Of the five analysts covering PetMed Express (PETS) in October 2017, two gave it “strong buy” ratings, two gave it “hold” ratings, and one gave it a “sell” rating. Its target price was $43.75.
Wall Street’s Forecast for Flotek Industries before Its 3Q17 Earnings
On October 16, 2017, all analysts tracking Flotek Industries rated it as a “buy” or some equivalent.
Analysts’ Recommendations for The Medicines Company in October
In 2Q17, The Medicines Company (MDCO) reported revenues of $18.7 million, which is a fall of 66.0% on a YoY (year-over-year) basis.
Why Structural Hurdles Could Thwart US Economic Progress
The American economy is facing major structural issues that have the potential to thwart economic progress. The most important hurdle facing the US economy is an aging population.
Ligand Pharmaceuticals Projects Higher Average Royalty Rate for Promacta
Ligand Pharmaceuticals (LGND) receives royalties from Novartis on Promacta’s sales according to a tiered annual payment structure.
Analysts’ Recommendations for Ligand Pharmaceuticals and Peers in 2017
In 2Q17, Ligand Pharmaceuticals (LGND) reported revenues of ~$28.0 million, representing year-over-year growth of ~43.4%. LGND received ~$14.2 million in royalties, a year-over-year rise of 45.7%.
Flotek Industries’ Stock Price Forecast on August 10
Flotek stock will likely close between $6.42 and $5.50 in the next seven days. Flotek’s stock price was $5.96 on August 10, 2017.
A Look at Flotek Industries’ Debt Position in 2Q17
In 2Q17, Flotek Industries’ (FTK) total debt fell ~34% compared to 2Q16.
What Could Drive Flotek Industries’ Growth?
Flotek Industries’ (FTK) management expressed optimism about improving pricing for FTK’s complex nano-Fluid (or CnF) products despite higher raw material costs.
What’s Flotek Industries’ Stock Price Forecast on July 3?
On July 3, 2017, Flotek’s (FTK) implied volatility was ~58%. Since its 1Q17 earnings were announced on May 3, 2017, FTK’s implied volatility has remained unchanged.
Is Flotek’s Debt Rising or Falling?
In 1Q17, Flotek Industries’ (FTK) total debt fell ~19% on a YoY basis. Its cash and marketable securities fell 26% during the same period.
Inside Flotek Industries’ Growth Drivers in 2Q17
Flotek’s management expects an optimum recovery in energy reservoirs by upstream operators, which has already started to push demand for FTK’s technology.
Short Interest in Tidewater Fell: What Does It Mean?
The short interest in Tidewater (TDW) stock as a percentage of its float was 27.6% as of January 18—compared to 37.3% as of September 30, 2016.
What Are Flotek Industries’ Future Drivers?
What does Flotek Industries’ management think? Flotek Industries’ (FTK) management believes the company resisted energy market weakness through steady performance in the energy chemistry segment. In the company’s 3Q16 conference call, Flotek Industries CEO John Chisholm stated that “we feel fortunate that our focus on high-end value added technology, especially in our energy chemistry segment […]
Why Did H.B. Fuller’s Construction Products Revenue Fall?
H.B. Fuller’s (FUL) Construction Products segment reported revenue of $64.4 million in 3Q16, which is 12.6% of the company’s total revenue.
Will Flotek Industries Reduce Its Debt?
Flotek Industries’ net debt-to-trailing 12 month adjusted EBITDA (earnings before interest, tax, depreciation, and amortization) rose from 2Q15 to 2Q16.
What Are Flotek Industries’ Future Growth Drivers?
Flotek Industries’ (FTK) management considers the current energy market environment to be challenging for the oilfield services industry.
What Is Ligand Pharmaceuticals’s Expected Revenue Growth in 2016?
Ligand Pharmaceuticals (LGND) is a high-growth company with a comparatively low-risk business model. It earns most of its revenue from royalty and license fees.
Why Did Analysts Raise EBITDA Margin and EPS Estimates for Papa John’s?
Analysts have revised their estimated EBITDA margins for Papa John’s (PZZA) for next four quarters.
Investing Do’s and Don’ts from Richard Bernstein
Richard Bernstein advises against trying to time the markets. What happens more often than not is that retail investors end up buying high and selling low—the opposite of what they should be doing.
Why Warren Buffett Strongly Believes in the American Dream
Buffett said that it has been a terrible mistake to bet against America, not only for the past 240 years but even now. He believes that America’s emphasis on innovation and strength in commerce will continue to provide strong gains for its people.
EdR’s Price-to-FFO Multiple Is Higher than Industry Average
A closer look at EdR’s (EDR) trailing-12-month price-to-FFO multiple shows that it is in line with its historical valuation.
Investing in Education Realty Trust: A Must-Know Company Overview
Education Realty Trust is a self-managed and self-administered equity REIT. The main objective of the company is to develop, acquire, own, and manage student housing properties.
How Can Century Aluminum Manage the Current Downtrend?
Fortunately for Century Aluminum, its leverage ratios are currently much lower than other companies in this space. CENX has $123 million in cash that should help it manage its operations over the next few quarters
Why Century Aluminum’s Shipments Could Fall More
Century Aluminum’s (CENX) consolidated shipments in 3Q15 were down 1% as compared to 2Q15. In 4Q14, CENX had acquired Alcoa’s stake in the Mt. Holly smelter.
What Are Analyst Recommendations for Vasco Data Security?
Vasco Data Security (VDSI) has generated returns of -25.5% in the trailing 12 months and 3.0% in the trailing-one-month period.
AK Steel’s 2Q15 Earnings and Outlook
AK Steel (AKS) reported its 2Q15 earnings on July 28. The company’s share price rose significantly after it released its second quarter results.
World Steel Production Declined in April
According to data released on May 25 by the WSA, world crude steel production totaled 135 million tons in April. This is a decline of 1.7% YoY.
Is the Steel Industry Gaining Strength?
This year, steel companies have had a mixed performance on Wall Street. However, there are signs of a revival in the steel industry.